You are here

Article Text

Article menu
Download PDFPDF
Case report
Disseminated cutaneous Mycobacterium haemophilum infection in a patient on infliximab for rheumatoid arthritis
  1. Samuel Harder1,
  2. Sarah Oberholtzer2,
  3. Geoffrey Shumilak2 and
  4. Beverly Wudel1,2
  1. 1College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
  2. 2Department of Medicine, Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada
  1. Correspondence to Dr Beverly Wudel; beverly.wudel{at}saskhealthauthority.ca

Abstract

Mycobacterium haemophilum is a rarely encountered pathogen that is difficult to identify given its unique growth requirements. It is most often seen in adult patients who are immunosuppressed due to advanced HIV or haematological malignancy. Our case highlights a typical presentation of an atypical pathogen in a patient with rheumatoid arthritis receiving anti-tumour necrosis factor therapy. This case represents an important patient population in whom this previously rare infection is increasingly common.

  • infections
  • rheumatoid arthritis
  • unwanted effects / adverse reactions
  • biological agents

https://doi.org/10.1136/bcr-2021-245853

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @BWudel

    • Contributors SH conceptualised and wrote the manuscript with contributions in intellectual content from SO and GS. Patient was initially under the care of GS with ongoing follow-up care by BW. Supervision of the report was by BW.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.